Login
$AGEN
$6.35 +$0.06 (0.95%) After hours

Consolidated Balance Sheets

In millions of USD, except per-share amounts
Q3 FY2026
As of Sep 30, 2026
Q2 FY2026
As of Jun 30, 2026
Q1 FY2026
As of Mar 31, 2026
Q4 FY2025
As of Dec 31, 2025
Q3 FY2025
As of Sep 30, 2025
Q2 FY2025
As of Jun 30, 2025
Q1 FY2025
As of Mar 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q3 FY2024
As of Sep 30, 2024
Q2 FY2024
As of Jun 30, 2024
Q1 FY2024
As of Mar 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Q2 FY2022
As of Jun 30, 2022
Q1 FY2022
As of Mar 31, 2022
Q4 FY2021
As of Dec 31, 2021
ASSETS
Cash and cash equivalents
Short-term investments
Zydus agreements escrow receivable (Note R)
Zydus agreements contract assets (Note R)
Accounts receivable
Prepaid expenses
Related party note receivable from MiNK Therapeutics, Inc.
Related Parties
Total related party note receivable from MiNK Therapeutics, Inc.
Assets held for sale
Other current assets
Total current assets
Property, plant and equipment, net of accumulated amortization and depreciation of $48,388 and $47,468 at September 30, 2026 and December 31, 2025, respectively
Operating lease right-of-use assets
Goodwill
Acquired intangible assets, net of accumulated amortization of $17,560 and $17,325 at September 30, 2026 and December 31, 2025, respectively
Equity method investment in MiNK Therapeutics, Inc.
Due from related party (MiNK Therapeutics, Inc.)
Other long-term assets
Total assets
LIABILITIES AND STOCKHOLDERS' DEFICIT
Short-term debt
Current portion, liability related to sale of future royalties and milestones (Note H)
Current portion, deferred revenue
Current portion, operating lease liabilities
Accounts payable
Accrued liabilities
Liabilities held for sale
Other current liabilities
Total current liabilities
Long-term debt
Liability related to sale of future royalties and milestones, net of current portion (Note H)
Deferred revenue
Operating lease liabilities, net of current portion
Other long-term liabilities
STOCKHOLDERS" DEFICIT
Series A-1 convertible preferred stock; 31,620 shares designated, issued, and outstanding at September 30, 2026 and December 31, 2025; liquidation value of $34,480 at September 30, 2026
Common stock, par value $0.01 per share; 800,000,000 shares authorized; 45,208,556 and 35,320,397 shares issued and outstanding at September 30, 2026 and December 31, 2025, respectively
Additional paid-in capital
Accumulated other comprehensive loss
Accumulated deficit
Total stockholders' deficit attributable to Agenus Inc.
Non-controlling interest
Total stockholders' deficit
Total liabilities and stockholders' deficit

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support